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Abstract 
 
BACKGROUND: The clinical effects of alkaptonuria (AKU) is delayed and ageing influences 
disease progression. Morbidity of AKU is secondary to high circulating homogentisic acid 
(HGA) and ochronosis. It is not known whether HGA is produced by or processed in the kidney 
in AKU. 
METHODS: Data from AKU patients from four studies were merged to form a single AKU 
group. A control group of non-AKU subjects was generated by merging data from two non-
AKU studies. Data were used to derive renal clearance and fractional excretion (FE) ratios for 
creatinine, HGA, phenylalanine (PHE) and tyrosine (TYR) using standard calculations, for 
comparison between the AKU and the control groups.  
RESULTS: There were 225 AKU patients in the AKU group and 52 in the non-AKU control 
group. Circulating HGA increased with age (p<0.001), and was statistically significantly 
associated with decreased HGA clearance (CLHGA) (p<0.001) and FEHGA (p<0.001). CLHGA and 
FEHGA were increased beyond the theoretical maximum renal plasma flow, confirming renal 
production and emphasizing the greater contribution of net tubular secretion than glomerular 
filtration to renal elimination of HGA.  
CONCLUSIONS: The kidneys are crucial to elimination of HGA. Elimination of HGA is 
impaired with age resulting in worsening disease over time. The kidney is an important site for 
production of HGA. Tubular secretion of HGA contributes more to elimination of HGA in 
AKU than glomerular filtration does.  
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Introduction 
Increasing age and male gender are associated with a more severe disease manifestation in the 
rare disease, alkaptonuria (AKU) (OMIM#203500) (1). A genetic deficiency of homogentisate 
dioxygenase (HGD) (EC:1.13.11.5) results in overproduction of homogentisic acid (HGA) due 
to an inability to fully metabolise ingested phenylalanine (PHE) and tyrosine (TYR), surplus to 
daily needs (2) and the TYR that is generated during protein turnover. Increased circulating 
HGA is directly causal in the disease process known as ochronosis, in which yellow-black 
pigment is formed (3), and deposited in connective tissues, especially cartilage, causing the 
connective tissue to become brittle and ultimately breakdown. Circulating HGA is maintained 
at a relatively low concentration because of efficient renal excretion, to the extent that the 
concentration of HGA in the urine is more than 1000-fold higher than in the circulation (4). 
However, other than the fact that renal secretion is crucial to eliminate HGA and minimise 
progression of disease in AKU, little is known in terms of how HGA is handled by the kidney.  
 
The frequency of AKU is around 1 in 250,000 to 1 in 1,000,000 in most populations worldwide 
making it a difficult condition to study reliably (5). In unaffected humans, significant expression 
of HGD has only been shown in the liver and the kidney (6). AKU is present from birth but the 
onset of morbidity is delayed for reasons that are yet to be fully understood. HGA is water 
soluble and freely eliminated via the kidney, despite which circulating HGA increases. There 
has not been a previous study specifically examining the renal handling of HGA in AKU 
beyond its renal excretion. This lack of data on renal handling of HGA is partly due to the 
difficulty in generating reliable plasma or serum measurements as HGA is labile and present in 
low concentrations compared to urine (7, 8).  
 
The debilitating manifestations of AKU include premature arthritis, cardiac valve disease, 
fractures, and ruptures of muscle and tendon (5); tissue ochronosis in kidneys has not been 
previously described even though the pigmented proteinaceous tubular casts have been 
described in the macroscopically grey pigmentation of the medullae (9). The excessive renal 
elimination of HGA can lead not only to dark urine but also renal stones (10). Renal function 
declines with ageing in non-AKU subjects, but it is not known if such a decline is present in 
AKU, although it has been postulated as a cause of the delayed appearance of the 
musculoskeletal symptoms of the disease despite the biochemical manifestation being present 
from birth (11). Renal failure has been shown to markedly accelerate ochronosis as well as the 
morbidity of AKU (12). Intractable fatal haemolysis in renal failure has been described in a 
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series of cases (13, 14). Conversely, renal transplantation for end-stage renal failure in AKU 
has improved the metabolic manifestations such as decreasing serum and urine HGA (12). A 
recent study in AKU reported changes in urine C3M, a biomarker reflecting the remodelling of 
the renal tissue, associated with a change in fibrogenesis in the kidneys (15, 16).  
 
Our group has carried out studies in AKU patients in whom similar data were collected at 
baseline without any HGA-lowering treatment. The studies from which baseline data were 
extracted to form the dataset presented in this manuscript are SONIA 1 and 2 (Suitability of 
Nitisinone in Alkaptonuria 1 and 2), SOFIA (Subclinical Ochronosis Features In Alkaptonuria), 
as well as data collected in the United Kingdom National Alkaptonuria Centre (NAC) (4, 17, 
18). This has allowed the generation of the largest dataset in AKU to date and should allow a 
better understanding of the condition. The objective in this manuscript is to clarify the effects 
of ageing and gender on metabolism in AKU, as well as to investigate the role of the kidney in 
AKU. 
 
Methods 
Patients 
AKU patients, verified by elevated urine HGA concentrations, and at least 16 years old were 
eligible for inclusion from SONIA 1 (4) and 2, SOFIA (15) and the NAC (17, 18). Two non-
AKU control groups were also available and merged to increase patient numbers (one of these 
was recruited as part of SOFIA, and the other was recruited separately (NRES [United Kingdom 
National Research Ethics Service] No:07/H1002/111), in parallel with SONIA 1. The United 
Kingdom NRES granted ethics approval for SONIA 1 (REC No:13/NW/0024; IRAS:121963; 
EUDRACT No:2012-005340-24), SONIA 2 (REC No:13/NW/0567; IRAS:136411; 
EUDRACT No:2013-001633-41), and SOFIA (REC N.:15/NW/0749; IRAS:180968). The data 
collected from the NAC was approved by the Institutional Audit Committee (Audit 
No:ACO3836). None of the patients in this study received HGA-lowering treatment at the time 
of participation. The data from the AKU patients in NAC, SONIA 1, SONIA 2 and SOFIA 
were merged to derive the combined AKU group. Patients from SONIA 1 also then took part 
in SONIA 2; patients from SONIA 2 and the NAC took part in SOFIA, and therefore 
duplication of data was avoided by including them once only in the merged group. Similarly, 
data from the two non-AKU studies were merged to derive a combined non-AKU control group.  
 
ASSESSMENTS 
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Study protocols have been described in detail previously for SONIA 1, SOFIA and NAC; a 
single morning blood and 24-h urine collections from SONIA 2 patients were similar to those 
collected in SONIA 1. These samples were collected in each patient for measurement of 
metabolites such as creatinine (CR), PHE, TYR, and HGA. In SONIA 1, 24-h blood samples 
were collected at baseline (0) and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 15, 18 and 24 hours after the 
morning sample, for determination of serum HGA (sHGA), serum TYR (sTYR) and serum 
PHE (sPHE). All serum and urine samples were acidified on collection as previously described 
to stabilise the HGA (4, 17). Serum and urine HGA, PHE and TYR, were measured by liquid 
chromatography tandem mass spectrometry (LC-MS/MS) methods, again described in detail 
elsewhere (4, 17, 20). CR, including serum (sCR), was measured by the Jaffe reaction (Roche 
Diagnostics, Germany) because HGA interferes with the enzymatic measurement of CR (21).  
 
Derived data:  
From the 24-h profiles of sHGA, sTYR and sPHE, only available for the SONIA 1 cohort, the 
mean concentration in this period was calculated as the area under the curve, determined by the 
trapezoidal rule, and divided by 24. The data presented on SONIA 1 (Table S1) represents 
calculations using mean 24-h serum HGA, TYR and PHE. The combined AKU data likewise 
includes calculations using mean 24-h serum HGA, TYR and PHE, for SONIA 1, but single 
fasting values for the NAC, SONIA 2 and SOFIA (in which 24-h profiles were not available). 
The estimated glomerular filtration rate (eGFR) was derived from the UK Kidney MDRD 
equation, 186 x (Creatinine/88.4)-1.154 x (Age)-0.203 x (0.742 if female) x (1.210 if black), 
employing sCR and other data pertaining to each patient (22). 
Creatinine clearance (CLCR) was derived from the equation [urine creatinine (micromoles) x 
urine volume (millilitres)] / [sCR (micromoles) x 1440 (minutes)]. Clearances for HGA, TYR 
and PHE (CLHGA, CLTYR, CLPHE) were derived in the same manner by substituting HGA or 
TYR or PHE for creatinine in the equation in the same manner. 
24-hour urinary excretion of HGA, TYR and PHE were derived by multiplying concentrations 
(micromoles per litre) by urine volume in litres (uHGA24, uTYR24, uPHE24). 
The Fractional Excretion of HGA (FEHGA) was calculated by the following equation and 
expressed as a percentage: 100 x [Urine HGA (micromoles per litre) x sCR (micromoles per 
litre)] / [Urine creatinine (micromoles per litre) x sHGA (micromoles per litre)]. The same 
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method was used to derive FETYR and FEPHE (23). The formula for FE, for example 
HGA, consists of two parts: firstly, figuring out how much HGA is excreted in the urine, by 
multiplying the urine HGA concentration by the urinary flow rate urinary flow rate, the 
numerator in the equation. Secondly, then finding its ratio to the total amount of HGA that 
passed through the kidney glomerulus, calculated by multiplying the plasma HGA 
concentration by the GFR, calculated using creatinine filtration. 
The contribution of glomerular filtration, tubular secretion and renal production to total renal 
HGA elimination was calculated based on the CLHGA, assuming a theoretical maximum of 
glomerular filtration of 120 mL/min and renal plasma flow of 600 mL/min. For example, if the 
CLHGA was greater than 600, say 900 mL/min, then glomerular filtration contribution would be 
120/900, tubular secretion would be 480/900 and renal production would be 300/900 and when 
expressed as a percentage would be 13.4%, 53.3% and 33.3% approximately. If the CLHGA was 
600 mL/min or less, then filtration was derived as (120/CLHGA) x 100 as a percentage; the 
secretion was derived as ([CLHGA-120]/CLHGA) x 100 as a percentage; production was assumed 
to be zero. (it was also considered whether to use a 20%/80% estimate when values were 600 
and below but it was felt the approach used was better; equally using the GFR from patients 
themselves seems attractive – in fact FEHGA – does just that – but since creatinine secretion may 
possibly be further increased in AKU, this may mislead and lead to underestimation of 
filtration). 
STATISTICAL ANALYSIS 
Continuous variables are presented using a mean and a standard deviation (SEM) whereas 
categorical variables are presented as frequencies. Parametric tests using unpaired ‘t’ test were 
employed in order to detect differences in demographic, chemical and metabolic characteristics 
between AKU and control groups as also between male and female AKU patients. Simple linear 
regressions were the main analyses generated. Outcome variables were plotted against age and 
other potential predictor data and regression analyses were carried out. Comparisons with 
controls were made as appropriate. A two-sided significance level of p values less than 0.05 
was used throughout. All analyses were conducted using Graphpad Instat 3™ software and 
figures were generated by Deltagraph 7™ software. 
 
Results 
Data from 225 AKU patients (140 male, 85 female) were collated from 37, 90, 30 and 68 
patients attending SONIA 1, SONIA 2, SOFIA and NAC, respectively. There were also normal 
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control data from 30 subjects in the SOFIA study and 22 subjects from an earlier study where 
normal data was collected. The demographic data of the individual studies are shown in 
Supplementary Table 1, including control studies 1 and 2. Data from SONIA 1 included 24-h 
serum profiles on HGA, TYR and PHE and were used to derive all the indices instead of single 
morning values (Table S2, Figures S5 and S6). Results described as increased or decreased 
were all statistically significant with p values shown in tables or text. 
Table S1. Demographic, chemical and metabolic data in all studies 
 NAC SONIA 1 SONIA 2 
SOFIA 
AKU 
SOFIA  
CONTROL 
STUDY 1* 
SONIA 1 
CONTROL 
STUDY 
Number (M/F) 68 (44/24) 37 (24/13) 90 (57/33) 30 (15/15) 30 (13/17) 22 (11/11) 
Age years 48.2±1.9 47.7±2.0 48.3±1.1 40.4±2.8 38.1±2.2 42.7±2.5 
sCR µmol/L 72±1.5 58±2.1 62.8±1.4 70.4±2.7 75±1.8 88±3.1 
eGFR 
mL/min/1.73m2 
102±2.3 131±4.2 120±3.1 104±4 93±2.6 78±1.8 
CLCR mL/min 88±4.1 157±10 117±4.3 106±5.4 NA 103±5.1 
sHGA µmol/L 29.8±1.8 35.6±1.5 29.0±1.1 29.1±1.4 NA NA 
sTYR µmol/L 54.8±4.0 59.6±1.6 63.8±1.7 58.6±2.1 62.8±2.4 58.4±3 
sPHE µmol/L 64.5±1.6 56.3±1.3 57.6±1.1 54.9±1.3 68.1±2.6 59.5±1.9 
uHGA24 µmol/day 22293±1121 33605±1770 32797±1308 37450±2368 NA  NA 
uTYR24 µmol/day 101.3±10.4 113.3±19.9 203.2±18.9 144.1±13.2 NA 73.5±13.3 
uPHE24 µmol/day 64±6.6 95.8±9.3 133±29.5 85.9±6.3 NA 50.3±6.8 
CLHGA mL/min 617±44.4 684±42 844±40 932±66 NA NA 
CLTYR mL/min 1.44±0.2 1.31±0.2 2.34±0.2 1.7±0.1 NA  0.86±0.15 
CLPHE mL/min 0.48±0.04 1.2±0.12 1.0±0.18 0.73±0.08 NA  0.42±0.06 
FEHGA%  699±36 442±15 731±23 884±45 8.4±0.86 0.43±0.05 
FETYR% 1.57±0.17 0.32±0.09 2.19±0.24 1.61±0.11 0.88±0.07 0.77±0.1 
FEPHE% 0.76±0.06 0.11±0.01 1.63±0.46 1.03±0.06 0.46±0.03 0.44±0.07 
*Only random urine was collected and some derived data not available 
Data expressed as Mean±SEM 
CLCR or creatinine clearance; CLHGA or HGA renal clearance; CLPHE or phenylalanine renal clearance; CLTYR 
or tyrosine renal clearance; FEHGA or fractional renal excretion of HGA; FEPHE or fractional renal excretion 
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of phenylalanine; FETYR or fractional renal excretion of tyrosine; sCR or Serum creatinine; sHGA or serum 
HGA; sPHE or serum phenylalanine; sTYR or serum tyrosine; uHGA24 or daily HGA excretion; uPHE24 or 
daily phenylalanine excretion; uTYR24 or daily tyrosine excretion. 
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Comparison of Combined AKU with Combined Controls 
All data from the combined AKU and combined non-AKU controls are shown in Table 1. As 
expected, all metabolic data such as sHGA, uHGA24, CLHGA, and FEHGA were statistically 
Table 1. Comparison of combined AKU and combined non-AKU Controls 
 COMBINED AKU COMBINED CONTROLS 
Number (M/F) 225 (140/85) 52 (24/28) 
Age years 47.1±0.9*** 40.1±1.7 
sCR µmol/L 65.8±0.9*** 80.5±1.9 
eGFR mL/min/1.73m2 114±1.8*** 86.6±2 
CLCREAT mL/min 113.6±3.2 103±5.1 
sHGA µmol/L 30.4±0.8*** 2.24±0.25 
sTYR µmol/L 59.7±1.2 60.9±1.9 
sPHE µmol/L 59.1±0.7** 64.7±1.8 
uHGA24 µmol/day 30376±837*** 1.94±0.12 
uTYR24 µmol/day 152±9.6* 73.5±13.3 
uPHE24 µmol/day 100±12.4*** 50.3±6.8 
CLHGA mL/min 763±24.7*** 0.43±0.03 
CLTYR mL/min 1.82±0.12*** 0.86±0.15 
CLPHE mL/min 0.84±0.08*** 0.42±0.06 
FEHGA%  694±17.5 5.03±0.74 
FETYR% 1.64±0.12 0.83±0.06 
FEPHE% 1.08±0.19 0.45±0.03 
P values: *<0.05; **<0.01; ***<0.001; Parametric unpaired t test was used; Data expressed as Mean±SEM 
CLCR or creatinine clearance; CLHGA or HGA renal clearance; CLPHE or phenylalanine renal clearance; 
CLTYR or tyrosine renal clearance; FEHGA or fractional renal excretion of HGA; FEPHE or fractional renal 
excretion of phenylalanine; FETYR or fractional renal excretion of tyrosine; sCR or Serum creatinine; 
sHGA or serum HGA; sPHE or serum phenylalanine; sTYR or serum tyrosine; uHGA24 or daily HGA 
excretion; uPHE24 or daily phenylalanine excretion; uTYR24 or daily tyrosine excretion. 
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significantly different in the AKU group compared with the non-AKU control group. However, 
sCR was significantly lower in AKU group compared with the non-AKU controls; conversely, 
eGFR as well as CLCR were significantly higher in AKU group compared with the non-AKU 
controls (Supplementary Figure 1). Further, sPHE was lower, and uTYR24, uPHE24, CLTYR and 
CLPHE were higher in AKU group compared with non-AKU controls. 
                 
Gender comparisons 
The male AKU patient group was compared with the female AKU group (Figure 1; Table 2). 
sCR as well as CLCR were statistically significantly higher in male AKU compared with female 
AKU patients. Although sHGA was similar in male and female AKU groups, uHGA24 was 
increased in male AKU subjects compared with the female AKU group. sTYR was increased 
in male AKU subjects compared with female AKU subjects. 
 
Renal elimination of HGA 
Figure 2 shows the CLHGA and FEHGA in the male and female AKU subjects. It is clear that 
elimination of HGA by the kidney is through glomerular filtration (smallest component), and 
through net renal tubular secretion (larger component than glomerular filtration); values noted 
for CLHGA and FEHGA in both male and female AKU patients are above the theoretical 
maximum of renal plasma flow of 600 mL/min. Renal elimination is greater than the theoretical 
maximum, namely the elimination of all of the metabolites contained in the total renal plasma 
flow. The elimination of HGA is greater than the combined total of the glomerular filtration 
and net tubular secretion. Supplementary figures 5 and 6 show individual studies, including 
SONIA 1 where 24-h mean serum concentration was used for derived indices instead of single 
sample values. The contribution of glomerular filtration, tubular secretion and renal production 
to total renal HGA elimination was calculated as previously described for SONIA 1 (where 
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mean 24-h serum HGA values were available), as well as the other AKU studies including the 
combined AKU group are shown in Table S3 and Fig S7. 
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Table 2. Comparison of Male and Female AKU Groups 
 Male AKU Female AKU 
Number  140 85 
Age years 46.1±1.1 48.8±1.4 
sCR µmol/L 70.8±1.1*** 57.5±1.3 
eGFR mL/min/1.73m2 116.2±2.0 110.5±3.5 
CLCREAT mL/min 119±3.4* 105.1±6.1 
sHGA µmol/L 31.4±0.96 28.7±1.3 
sTYR µmol/L 62.9±2.1*** 54.4±1.5 
sPHE µmol/L 60.1±0.87 57.5±1.3 
uHGA24 µmol/day 32525±976*** 26836±1454 
uTYR24 µmol/day 161±11.8 137±16.6 
uPHE24 µmol/day 95.2±6.1 108.8±31.3 
CLHGA mL/min 779±30 720±43 
CLTYR mL/min 1.87±0.14 1.75±0.21 
CLPHE mL/min 0.81±0.05 0.9±0.19 
FEHGA%  686±21 708±30 
FETYR% 1.56±0.12 1.78±0.24 
FEPHE% 0.88±0.06 1.39±0.49 
P values: *<0.05; **<0.01; ***<0.001; Parametric unpaired ‘t’ test with Welch Correction (2-
tail); Data expressed as Mean±SEM 
CLCR or creatinine clearance; CLHGA or HGA renal clearance; CLPHE or phenylalanine renal 
clearance; CLTYR or tyrosine renal clearance; FEHGA or fractional renal excretion of HGA; FEPHE 
or fractional renal excretion of phenylalanine; FETYR or fractional renal excretion of tyrosine; 
sCR or Serum creatinine; sHGA or serum HGA; sPHE or serum phenylalanine; sTYR or serum 
tyrosine; uHGA24 or daily HGA excretion; uPHE24 or daily phenylalanine excretion; uTYR24 or 
daily tyrosine excretion. 
 
Linear regression analyses 
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Simple linear regression analyses were carried out on data from the combined AKU group and 
shown in Table 3. Age is a significant positive predictor of sHGA, but CLCR, uHGA24, CLHGA 
and FEHGA showed the strongest negative relationship to age (Supplementary Figure 2). eGFR 
also showed a positive linear relationship with creatinine clearance, uHGA24 and CLHGA; a 
negative linear relationship was also seen with sHGA (Supplementary Figure 3). sHGA showed 
a positive linear relationship with uHGA24 and statistically significant negative linear 
relationship between CLHGA and FEHGA. Serum tyrosine was positively related to uHGA24 as 
well as to CLHGA. uHGA24 was positively associated with CLHGA, as well as with uTYR24, 
uPHE24, CLTYR, CLPHE, FETYR and FEPHE. CLHGA, CLTYR, CLPHE, FETYR and FEPHE were all 
found to be significant positive predictors of uPHE24. The linear relationships between sHGA, 
uHGA24, CLHGA and FEHGA are graphically represented in Supplementary Figure 4. 
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Table 3. REGRESSION ANALYSIS ON COMBINED AKU GROUP 
 Age eGFR sCR CLCR sHGA sTYR sPHE uHGA24 uTYR24 uPHE24 CLHGA CLTYR CLPHE FEHGA FETYR FEPHE 
Age  -0.17 -0.12 -0.22 0.31 -0.01 -0.02 -0.18 -0.16 -0.03 -0.38 -0.16 -0.02 -0.26 -0.06 0.01 
eGFR   -0.75 0.61 -0.16 0.13 -0.11 0.26 0.12 0.01 0.34 0.07 0.03 -0.19 -0.17 -0.11 
sCR    -0.41 0.16 -0.02 0.18 -0.07 -0.03 -0.03 -0.16 -0.01 -0.06 0.21 0.12 0.05 
CLCR     -0.06 0.17 -0.03 0.64 0.28 0.1 0.58 0.21 0.15 -0.23 -0.21 -0.11 
sHGA      0.09 0.17 0.23 -0.08 -0.04 -0.47 -0.13 -0.01 -0.57 -0.16 -0.06 
sTYR       00.11 0.19 0.18 0.04 0.27 -0.1 -0.01 0.13 -0.15 0.02 
sPHE        -0.05 -0.01 -0.04 -0.14 -0.01 -0.14 -0.15 -0.01 -0.07 
uHGA2
4 
        0.27 0.11 0.65 0.16 0.11 0.13 -0.13 -0.02 
uTYR24          0.45 0.26 0.90 0.43 0.05 0.69 0.33 
uPHE24           0.09 0.4 0.95 0.03 0.35 0.96 
CLHGA            0.18 0.06 0.62 -0.04 0.01 
CLTYR             0.41 0.03 0.85 0.3 
CLPHE              -0.03 0.33 0.89 
FEHGA               0.16 0.12 
FETYR                0.38 
FEPHE                 
Values in boxes in the table refer to correlation coefficients 
p values are colour coded: Yellow <0.05; Green <0.01; Blue <0.001; Red <0.0001 
Age – years; CLCR or creatinine clearance; CLHGA or HGA renal clearance; CLPHE or phenylalanine renal 
clearance; CLTYR or tyrosine renal clearance;  eGFR mL/min/1.73m
2;  FEHGA or fractional renal excretion of 
HGA; FEPHE or fractional renal excretion of phenylalanine; FETYR or fractional renal excretion of tyrosine; 
sCR or Serum creatinine; sHGA or serum HGA; sPHE or serum phenylalanine; sTYR or serum tyrosine; 
uHGA24 or daily HGA excretion; uPHE24 or daily phenylalanine excretion; uTYR24 or daily tyrosine excretion. 
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Figure S1. Comparison of combined AKU and combined non-AKU control groups (Box plots 
with square (mean) and horizontal line (median) inside the box). Upper panel shows eGFR 
comparison; middle panel shows sCR comparison; lower panel shows CLCR comparison. 
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Figure 1. Comparison of metabolic and other parameters in male and female AKU groups. (A) 
Upper panel shows eGFR comparison; middle panel shows sCR comparison; lower panel 
shows CLCR comparison between All, male and female AKU patients; (B) – comparison of 
sHGA between All, male and female AKU patients; (C) - comparison of uHGA24 between All, 
male and female AKU patients. P values are shown where significant (Box plots with square 
(mean) and horizontal line (median) inside the box). (eGFR – estimated glomerular filtration 
rate; sCR – serum creatinine; CLCR – creatinine clearance; sHGA – serum HGA; uHGA24 – 
24-h urine HGA).  
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Figure 2. CLHGA (A) and FEHGA (B) comparison in Male and Female AKU patients (Box plots 
with square (mean) and horizontal line (median) inside the box; GFR is glomerular filtration 
rate (green line); RPF is renal plasma flow (red line); Filtration: glomerular filtration; Secretion: 
net tubular secretion; Local production: tubular production). 
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Figure S2. Linear regression analysis of different parameters vs. age showing (A) – positive 
linear relationship between sHGA and age; (B) – a negative linear relationship between uHGA24 
and age; (C) – negative linear relationship between CLHGA and age; (D) – negative linear 
relationship between FEHGA and age (Solid blue line – linear regression; dotted blue line – 95% 
confidence interval). 
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Figure S3. Linear regression analysis of eGFR with other parameters showing (A) – negative 
linear relationship between sHGA and eGFR; (B) – positive linear relationship between 
uHGA24 and eGFR; (C) - positive linear relationship between CLHGA and eGFR ; (D) – 
negative linear relationship between FEHGA and eGFR (Solid blue line – linear regression; 
dotted blue line – 95% confidence interval). 
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Figure S4. Linear regression analysis of sHGA, uHGA24 and CLHGA with other parameters 
showing:  (A) – positive linear relationship between sHGA and uHGA24; (B) – negative linear 
relationship between sHGA and CLHGA; (C) - negative linear relationship between sHGA and 
FEHGA; (D) – positive linear relationship between uHGA24 and CLHGA; (E) - positive linear 
relationship between uHGA24 and FEHGA; (F) - positive linear relationship between CLHGA and 
FEHGA (Solid blue line – linear regression; dotted blue line – 95% confidence interval). 
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Figure 3a. Handling of phenylalanine, tyrosine and homogentisic acid in the kidney. Possible 
transporters are also shown. (TYR: tyrosine; PHE: phenylalanine; HPPA: 4-
hydroxyphenylpyruvic acid; HGA: homogentisic acid; Na: sodium; MRP 4: multiple 
resistance-associated protein 4 (ABC transporter); ATP: adenosine triphosphate; ADP: 
adenosine diphosphate; SLC6 A19: also known as BO or Sodium-dependant transporter or 
Solute Carrier Family 6 Member 19; OAT: organic anion transporter; αKG: alpha ketoglutarate; 
LAT 1: L-type amino acid transporter 1). Glomerular filtration, tubular secretion and tubular 
production of HGA in Combined AKU group is 15.7%, 62.9% and 27.4% respectively, to total 
HGA renal elimination. 
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Figure 3b. Creatinine excretion and the kidney. (MATE 1: Multidrug and toxin extrusion 
protein 1; OAT 2: Organic anion transporter 2; OCT: Organic cation transporter). 
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Discussion  
Our group has carried out assessments in AKU from four different cohorts, and by combining 
the data from these cohorts we have obtained the largest dataset in this rare disease. The 
individual data from the four separate cohorts are shown in Table S1. Merging data in this way 
also generated data with sufficient power to reliably compare gender and age differences in 
metabolism in AKU patients. 
 
Kidney and HGA, TYR and PHE: The HGA concentration in the body fluid compartments 
is the most important determinant of the evolution of AKU. The kidney is crucial in AKU as it 
has significant effects on tyrosine metabolism including handling of HGA thus maintaining low 
HGA levels within the body. Renal failure leads to accelerated disease in AKU while renal 
transplantation decreases serum and urine HGA (12, 13, 14). Glomerular filtration, tubular 
reabsorption and secretion are involved in dealing with circulating PHE, TYR and HGA, 
although their relative contribution in AKU is unknown. The kidney also expresses HGD (6) 
and should be able to metabolise phenylalanine and tyrosine via HGA to fumarate and 
acetoacetate in healthy and to HGA in AKU subjects; but this renal production of HGA has 
never been previously shown. However, an active tyrosine pathway causing nephropathy in 
hereditary tyrosinaemia type 1 (HT 1) is previously described, although the magnitude of the 
activity in the renal tyrosine pathway remains unknown (24).  
 
Glomerular filtration in AKU: Glomerular filtration in this dataset was assessed by eGFR 
(22) and traditional CLCR. There is a strong positive relationship between eGFR and CLCR 
confirming the robustness of using these parameters to assess renal glomerular function in the 
present analysis. CLCR, like eGFR, showed the expected decline with age (25). Contrary to 
expectations, eGFR was significantly increased, and serum creatinine significantly decreased, 
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in AKU compared with non-AKU controls, even though the AKU group was older; CLCR 
showed a trend to be higher in AKU than in non-AKU controls (single tail unpaired ‘t’ test 
p<0.04). This could be due to sarcopenia in AKU, a severely debilitating disease of spine and 
joints, in relation to eGFR. However, this cannot be the full explanation since CLCR is also 
trending to be higher in AKU subjects than in non-AKU controls. Further, eGFR is likely to be 
less useful in estimating glomerular filtration than in normal. 
 
Even in normal human subjects, CLCR does not only reflect glomerular filtration because there 
is also net tubular secretion of creatinine (26), suggesting that CLCR overestimates glomerular 
filtration. In terms of tubular secretion, creatinine has been shown to enter the renal tubular cell 
through the basolateral route via a number of transporters including organic anion transporter 
2 (OAT2) and organic cation transporters (OCT 1 and 2). Intracellular creatinine is then 
secreted into the urinary filtrate via the multidrug and toxin extrusion protein 1 and 2 (MATE 
1 and 2 or SLC47A1 transporter) apical transporters (Figure 3a) (27). With chronically 
increased serum levels of organic anions in AKU from birth (overproduction of HGA), we 
postulate that this leads to chronic compensatory upregulation of renal OAT 2 and possibly 
cation transporters, to increase HGA excretion (28, 29). HGA as an anion can, like creatinine, 
not only be filtered at the glomerulus, but also be secreted by the tubular cells. HGA tubular 
secretion is expected to follow a similar process to that for creatinine, being taken up into the 
tubular cell via basolateral OATs before the intracellular HGA is secreted into the urinary 
filtrate via the ABC-transporter protein, multiple resistance-associated protein 4 (MRP 4) (30) 
(Fig 3a, b; drawn based on current knowledge). It is therefore possible that the need to 
efficiently eliminate HGA also leads to more efficient creatinine elimination, lower serum 
creatinine, higher eGFR as well as a trend to increased CLCR in AKU patients. It is noteworthy 
that there is a significant amount of literature on factors decreasing creatinine tubular secretion 
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(31, 32) but not with respect to those increasing creatinine tubular secretion. 
 
Ageing and gender and AKU: AKU symptoms worsens with age (1). It is worth noting that 
besides a decreased CLCR and eGFR with age, older patients had increased sHGA, and 
decreased uHGA24; all of these findings can be explained by the observed decreased CLHGA 
and decreased FEHGA with ageing in the AKU group. Interestingly, decrease in uTYR24 and 
CLTYR with age may point to a common mechanism such as impaired tubular secretion or 
reduced blood flow with age. 
 
Female sex is associated with less severe and delayed disease progression compared to males 
(1). sCR was increased in male AKU compared with female AKU patients as one would expect; 
however, CLCR was increased in male AKU compared with female AKU consistent with the 
idea of more efficient creatinine secretion with higher HGA urinary excretion as already 
described. Although circulating HGA is similar in males and females, uHGA24 was increased 
in males; interestingly circulating TYR was increased in males without being accompanied by 
increased uTYR24 or CLTYR or FETYR, suggesting greater possible conversion of filtered TYR 
to HGA in the renal tubular cell in males before being excreted as HGA into the urinary filtrate.  
 
Role of kidney in tyrosine metabolism: With increasing CLCR, there is increased uTYR24, 
higher sTYR, greater CLTYR and more FETYR, which is consistent with the important role of the 
kidney in tyrosine metabolism. Higher sHGA associates with lower CLTYR and FETYR, as well 
as higher sPHE, possibly due to a common denominator of decreasing renal function. The 
higher sTYR was associated with greater uHGA24 suggesting renal tubular conversion to HGA 
prior to elimination in the urine; the higher sTYR was also related to higher uTYR24 and higher 
CLHGA, as expected due to greater tyrosine load in the kidney. Also, higher uHGA24 was 
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associated with greater uTYR24, increased CLTYR, consistent with the presence of an active 
tyrosine pathway in the kidney and renal tubular conversion of tyrosine to HGA. 
 
Greater uTYR24 was seen with higher uPHE24, higher CLPHE, and higher FEPHE, consistent with 
a renal tubular conversion of PHE to TYR; this was also supported by the finding of an 
association between higher uPHE24 linked to higher CLTYR, higher CLPHE, higher FETYR and 
higher FEPHE. While these relationships are suggestive and supportive of active renal tubular 
conversion of phenylalanine and tyrosine to HGA, it is realised that this is not proof of causal 
relationships. 
  
Components of renal HGA handling: If the circulating HGA increases, there is greater 
likelihood of ochronotic damage. Development of ochronosis is slow in AKU and is apparent 
around the second decade (1). The severity of AKU both in terms of ochronosis and its 
consequences of breakdown of tissues, increases with age. Therefore, elimination of HGA 
through the renal route as already mentioned is crucial (30). The observed CLHGA is very 
efficient, much higher than predicted by complete clearance of HGA from renal plasma in one 
pass, and cannot be explained solely by glomerular filtration and the quantitatively more 
important net tubular secretion; glomerular filtration and tubular secretion comprise 20% and 
80% of total elimination respectively, if these two were the only factors contributing to urinary 
HGA. The renal tubular cell can also take up HGA from the renal extracellular fluid via the 
organic anion transporters, such as OAT 1, OAT 2 and OAT 3 (33, 34, 35). Renal tubular HGA 
can then be eliminated via the ABC Transporter, MRP 4 (30), into the urine. Interestingly, 
creatinine is also handled via the OAT 2 in the basolateral membrane followed by excretion by 
the apical multidrug and toxin extrusion protein 1 (MATE 1) or SLC47A1 transporter, as 
already mentioned (32). In AKU due to the need to excrete large quantities of HGA anions from 
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birth, it is reasonable to postulate compensatory chronic over-expression of the OAT/MRP 
4/MATE 1 transporters (28, 29).  The clearance of HGA greater than the theoretical renal 
plasma flow is unphysiological (36), and can only be explained on the basis of local production 
of HGA through the presence of the full tyrosine pathway in the renal cells. The CLHGA data is 
also strongly supported by similar FEHGA data. This is the first time the magnitude of the renal 
contribution to the PHE/TYR pathway has been clearly demonstrated by data. It can also then 
be presumed that PHE and TYR filtered along with HGA in the glomerulus is reabsorbed via 
luminal solute transporter SLC6A19 (37, 38, 39) into the renal cell; the PHE and TYR can then 
be pumped out basolaterally into the extracellular fluid through the complex transporter, a 
glycoprotein termed CD98 that is a heterodimer composed of SLC3A2 and SLC7A5 (40). 
 
However, PHE and TYR can also be metabolised within the renal tubular cells to HGA in AKU 
and excreted in the urine; the deamination of tyrosine, by providing nitrogen, could contribute 
to ammonium generation by the renal tubular cells to maintain acid base balance, besides 
providing energy substrates to the cells through fumarate and acetoacetate.  
 
The limitation of the clearance analyses of HGA, TYR and PHE, due to lack of mean 24-h 
values needs to be pointed out, since single sample morning values were used instead for the 
data from NAC, SONIA 2 and SOFIA; obtaining mean 24-h values for all subjects is 
impractical. However, 24-h profiles from SONIA 1 were used to calculate mean serum 24-h 
values and shown in Table S2 and Fig S5. The mean 24-h serum values for TYR and PHE were 
very similar to single sample TYR and PHE values; however, mean 24-h serum values for HGA 
were higher than the single sample HGA, despite which CLHGA remained greater than the 
theoretical renal plasma flow (Figure S6). It is therefore believed that the analyses using single 
sample values of sHGA, sTYR and sPHE for CLHGA, CLTYR and CLPHE in the NAC, SONIA 2 
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and SOFIA is still meaningful. It is worth pointing out that the renal production of HGA was 
greatest in SOFIA, where the majority of patients were younger than 35 years of age (15). The 
24-h profiles for sHGA, sTYR and sPHE are also shown as Figure S5. Calculation of the 
contributions from glomerular filtration, tubular secretion and tubular production to renal 
elimination of HGA in the combined AKU group was estimated as percentages which were 
19.75, 60.68 and 19.67 respectively (Fig 3a, Table S3).  
 
In summary, we present data on tyrosine metabolism in AKU in the largest number of patients 
ever studied. As expected, the amount of HGA in the body fluids and urine is increased in AKU. 
The data shows the crucial part played by the kidneys in slowing down the progression of 
symptoms in AKU. The roles played by glomerular filtration, tubular secretion and local 
production of HGA are documented in this dataset. Possible molecular mechanisms for these 
processes are described for the first time. The filtered amino acids PHE and TYR may also 
contribute to the metabolic picture in AKU. 
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Table S2.  SONIA 1 Fasting and Mean 24-h circulating values (Mean±SEM; n = 40) 
 Fasting serum value Mean 24-h serum value 
sHGA (µmol/L) 29.2±1.3 36.5±1.5 
sTYR (µmol/L) 59.7±2.1 59.9±1.5 
sPHE (µmol/L) 58.9±1.4 59.7±1.0 
 
 
Table S3.  Proportion of renal production, renal tubular secretion  
and glomerular filtration to total renal HGA elimination assuming glomerular filtration  
of 120 mL/min and renal plasma flow of 600 mL/min 
 Glomerular filtration % Tubular secretion % Renal production % 
Combined AKU group (n=225) 19.75±0.74 60.68±1.04 19.67±1.41 
NAC (n=68) 25.86±1.92 61.59±1.85 12.64±2.33 
SONIA 1 (n=37) 19.56±1.08 67.14±1.91 13.30±2.62 
SONIA 2 (n=90) 17.03±0.79 59.14±1.70 23.82±2.32 
SOFIA (n=30) 14.87±1.07 54.80±2.82 30.33±3.82 
Values expressed as Mean±SEM 
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Figure S5 showing 24-hour serum profiles of PHE, TYR and HGA in SONIA 1 pre-nitisinone (n = 40) 
(Box plots with square (mean) and horizontal line (median) inside the box). 
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 Figure S6 showing CLHGA using mean 24-h serum HGA profile in SONIA 1 but single morning sHGA 
in the NAC, SONIA 2 and SOFIA showing comparable clearances of HGA in all 4 groups. Highest 
clearances in SOFIA containing the youngest patients. (Box plots with square (mean) and horizontal 
line (median) inside the box; GFR is glomerular filtration rate (green line). 
 
 
 
 
 
 
 
 
 
 
 
 
  
B
B
B
B
NAC SONIA 1 SONIA 2 SOFIA
0
500
1000
1500
C
L
H
G
A
 m
L
/m
in
GFR
RPF
[Type here] 
 
 37 
 
 
Fig S7. Proportions of renal tubular filtration, secretion and production contributing to renal 
HGA elimination (ALL: combined AKU group; NAC: National AKU Centre; SN1: SONIA 1; 
SN2: SONIA 2; SOF: SOFIA  
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